Olympus America Inc.
$2.8M 7,547 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, plc reported $2,796,389.90 across General Payments, Research, and Ownership to 26,764 physicians and teaching hospitals across 27,568 transactions.
- $2.8M
- All-tracks total
- 27,568
- Transactions
- 26,764
- Recipients
- #379
- of 1,925 companies
Kiniksa Pharmaceuticals International, plc reported $2,796,389.90 across all CMS Open Payments tracks (General + Research + Ownership) to 26,764 physicians and teaching hospitals in Program Year 2024 - ranking #379 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,744,692.94, averaging $104.48 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer kiniksa-pharmaceuticals-international-plc Kiniksa Pharmaceuticals International, plc
$2.8M · #379/1,925 · 0.0% industry · PY2024
- TOT $2.8M
- RANK #379
- SHARE 0.0%
- TXN 27,568
- RCP 26,764
- CAT 8
- GEN $1.7M
- TOP1 7.3%
- PY 2024
Volume peers
Nearest volume peer: Olympus America Inc. ($2.8M)
Kiniksa Pharmaceuticals International, plc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, plc ranks #379 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, a comparatively small 0.0% slice of all industry payments reported nationwide for the year. The underlying total is $2,796,389.90 across 27,568 transactions to 26,764 physicians and teaching hospitals - $101.44 per transaction and $104.48 per recipient on average.
26,095 transactions worth $626.1K make "Food and Beverage" the top general-payment category in the 8-category breakdown below, 35.9% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Kiniksa Pharmaceuticals International, plc made 8 types of general payments. "Food and Beverage" is the largest category at $626.1K, 35.9% of General Payments.
Kiniksa Pharmaceuticals International, plc reports 8 general-payment categories - the top three are Food and Beverage (35.9%), Compensation for Services Other Than Consulting (32.9%), and Space Rental or Facility Fees (14.6%). The remaining 5 categories make up 16.6% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: Kiniksa Pharmaceuticals International, plc files across 8 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How Kiniksa Pharmaceuticals International, plc divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $626.1K | 26,095 | 35.9% |
| Compensation for Services Other Than Consulting | $574.2K | 242 | 32.9% |
| Space Rental or Facility Fees | $255.3K | 43 | 14.6% |
| Royalty or License | $126.8K | 10 | 7.3% |
| Travel and Lodging | $88.6K | 337 | 5.1% |
| Consulting Fee | $52.3K | 32 | 3.0% |
| Education | $11.5K | 4 | 0.7% |
| Charitable Contribution | $10.0K | 1 | 0.6% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $363,342.67 (20.8%) of $1,744,692.94 in this company's General Payments records across 12,258 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Kiniksa Pharmaceuticals International, plc
The five named recipients with the highest reported General Payments from this company
- 1
Beth Israel Deaconess Medical Center
$126,759.79 across 10 reported transactions
- 2
John Ryan
$74,175.88 across 82 reported transactions
- 3
Robert Biederman
$58,792.74 across 58 reported transactions
- 4
David Homan
$55,187.61 across 68 reported transactions
- 5
John Isaac
$48,426.65 across 57 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Kiniksa Pharmaceuticals International, plc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Kiniksa Pharmaceuticals International, plc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Kiniksa Pharmaceuticals International, plc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Peter Brasseler Holdings, LLC
$2.8M 553 recipients
Compare payment profiles
Skeletal Dynamics Inc
$2.8M 1,938 recipients
Compare payment profiles
Cochlear Americas
$2.8M 1,888 recipients
Compare payment profiles
Philadelphia Medical Management Company LLC
$2.8M 4 recipients
Compare payment profiles
Orthalign Inc
$2.8M 713 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.